Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO).

Eye (London, England)·2023
Same author

Dermoscopy of blastic plasmacytoid dendritic cell neoplasm in two patients.

Clinical and experimental dermatology·2021
Same author

Symptomatic mucosal involvement in pachyonychia congenita: challenges in infants and young children.

The British journal of dermatology·2019
Same author

Nested case-control study investigating the diagnostic role of tissue eosinophilia in adverse cutaneous drug reactions.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Grover disease and bullous pemphigoid: a clinicopathological study of six cases.

Clinical and experimental dermatology·2018
Same author

Optogenetic approaches to vision restoration.

Experimental eye research·2018
Same journal

Tonographic outflow facility and intraocular pressure after standalone OMNI surgery.

Journal of glaucoma·2026
Same journal

Factors Associated With Retinal Nerve Fiber Layer Asymmetry in Primary Open-Angle Glaucoma Among Individuals of African Ancestry.

Journal of glaucoma·2026
Same journal

Haploinsufficiency of PITX2 in Four Chinese Families with Axenfeld-Rieger Syndrome.

Journal of glaucoma·2026
Same journal

Intraocular Pressure-Lowering Effect of Omidenepag Isopropyl as a Predictor for the Efficacy of Laser Trabeculoplasty.

Journal of glaucoma·2026
Same journal

Comparative Outcomes Between Micropulse and Slow-Coagulation Transscleral Cyclophotocoagulation in Eyes With Good Visual Acuity.

Journal of glaucoma·2026
Same journal

Machine Learning With Optical Coherence Tomography for Glaucoma Diagnosis.

Journal of glaucoma·2026
See all related articles

Related Experiment Videos

Glaucoma Filtering Surgery With Interferon-alpha-2b.

M C Gillies1, I Goldberg, S H Young

  • 1Department of Ophthalmology, Prince of Wales Hospital, and Pediatric Research Laboratory, Prince of Wales Children's Hospital, Randwick, Sydney, Australia.

Journal of Glaucoma
|November 19, 2009
PubMed
Summary
This summary is machine-generated.

Subconjunctival interferon-alpha-2b shows promise in glaucoma surgery. This treatment may improve success rates and reduce corneal complications compared to 5-fluorouracil, offering a potentially safer alternative for patients.

Related Experiment Videos

Area of Science:

  • Ophthalmology
  • Surgical Innovation
  • Pharmacological Research

Background:

  • Glaucoma filtering surgery success can be limited by scarring and inflammation.
  • 5-fluorouracil is a common antifibrotic agent used post-surgery, but it has associated complications.
  • Novel therapeutic agents are needed to improve surgical outcomes and patient tolerance.

Purpose of the Study:

  • To compare the efficacy and safety of subconjunctival interferon-alpha-2b versus 5-fluorouracil in maintaining success after glaucoma filtering surgery.
  • To evaluate the impact of different interferon-alpha-2b dosages on surgical outcomes and ocular side effects.
  • To assess the rate of corneal epithelial defects associated with each treatment.

Main Methods:

  • A pilot study comparing subconjunctival interferon-alpha-2b with 5-fluorouracil in patients undergoing glaucoma filtering surgery.
  • Surgery success was defined as intraocular pressure (IOP) < 21 mm Hg without medication.
  • Interferon-alpha-2b was administered at initial doses of 2 x 10^6 IU, later increased to 1 x 10^7 IU in a subset of patients.

Main Results:

  • At 6 months, 6/16 (37.5%) interferon-treated patients required medication resumption versus 2/16 (12.5%) 5-fluorouracil patients (p=0.08).
  • With the higher interferon dose (1 x 10^7 IU), only 2/13 (15.4%) patients needed medication (p=0.14 vs. lower dose).
  • Corneal epithelial defects were significantly less common with the higher interferon dose (1/13) compared to 5-fluorouracil (11/16; p=0.0002).

Conclusions:

  • Subconjunctival interferon-alpha-2b is well-tolerated in the doses studied.
  • Interferon-alpha-2b may reduce the risk of glaucoma filtration surgery failure.
  • Interferon-alpha-2b demonstrates a potential advantage over 5-fluorouracil due to fewer corneal complications.